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Abstract
Theoretical methods for predicting CD8+ T-cell epitopes are an important tool in vaccine design and for enhancing our
understanding of the cellular immune system. The most popular methods currently available produce binding affinity
predictions across a range of MHC molecules. In comparing results between these MHC molecules, it is common practice to
apply a normalization procedure known as rescaling, to correct for possible discrepancies between the allelic predictors.
Using two of the most popular prediction software packages, NetCTL and NetMHC, we tested the hypothesis that rescaling
removes genuine biological variation from the predicted affinities when comparing predictions across a number of MHC
molecules. We found that removing the condition of rescaling improved the prediction software’s performance both
qualitatively, in terms of ranking epitopes, and quantitatively, in the accuracy of their binding affinity predictions. We
suggest that there is biologically significant variation among class 1 MHC molecules and find that retention of this variation
leads to significantly more accurate epitope prediction.
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Introduction
Cytotoxic T lymphocytes (CTLs) discriminate between healthy
and pathogen-infected cells by recognizing and responding to a
molecular complex on the surface of the infected cell. This
complex consists of a specific major histocompatibility complex
(MHC) molecule and a peptide derived from the proteins
contained in the cell. If the cell contains a pathogen, peptides
from the pathogen proteome will be presented and, with the right
MHC – peptide complex, a CTL response will be elicited.
Of the large number of peptides that can be derived from a
pathogen only a small minority elicits a CTL response. This number
has been estimated to be between 1 in 2,000 and 1 in 5,600 [1,2].
This limitation in the number of peptides that are immunogenic is
conferred by three main constraints: the requirement for peptide
cleavage and transport, the requirement for MHC-peptide binding
and the requirement for CTL recognition. By far the most stringent
of these is the requirement for MHC-peptide binding, because only
1 in 40–200 peptides binds a specific MHCmolecule with sufficient
affinity to elicit an immune response [1,2]. Further selection is
largely due to the limitations of peptide processing and transport. In
these processes, individual peptides are produced from the
precursor polypeptides by proteasomal cleavage of the polypeptide,
which can be followed by N-terminal trimming by other peptidases.
This is followed by the transport of the peptides from the cytosol to
the endoplasmic reticulum, mediated by the TAP complex. Further
N-terminal trimming may occur before the peptide binds to the
MHC molecule. The requirements of processing and transport
eliminate approximately 80% of potential epitopes [1]. Finally, T
cell specificity, i.e. the requirement for T cell receptor binding of the
MHC-peptide complex, further halves the number of presented
peptides that elicit a response. The probability of each of these steps
is determined by the polypeptide sequence, amongst other factors
[3].
Once CTLs recognize the MHC-peptide complex, they are
capable of destroying the infected cell by the release of lytic
granules containing cytotoxic effector proteins. This results in the
destruction of the target cell by apoptosis. An effective CTL
response has been shown to confer protection against viral
infection, such as HIV [4] and HTLV-I [5]. Hence, the
identification of T cell epitopes is of vital importance in the
design of vaccines and understanding of the immune system
[6,7,8]. However, given the scarcity of epitopes, experimentally
screening all possible peptides for each MHC allele (e.g. by IFNc
ELISpot) is time consuming, expensive and inefficient. One way to
improve the efficiency of the identification process is to first use
theoretical algorithms to predict which peptides are more likely to
be epitopes and then experimentally screen this much smaller,
selected list of peptides. This method is widely used [9–12] and has
been applied in a number of studies to identify potential vaccine
targets [13,14]. The use of theoretical methods to ‘‘pre-screen’’
peptides is of particular importance in the case of emerging
infections such as avian influenza [15] where rapid vaccine
development would be vital. This approach underpins a large bio-
preparedness initiative coordinated by the Large-Scale Antibody
and T Cell Epitope Discovery Program [7], which intends to foster
development of immune-based therapeutics for emerging and
reemerging pathogens including potential bioterrorism agents.
The accuracy of these methods has also been demonstrated by the
prediction of the vast majority of CTL epitopes from the vaccinia
virus [16].
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More generally, epitope prediction algorithms are being
increasingly used to understand the CTL response. For example,
in the case of HIV-1 infection, algorithms have been used to
confirm which MHC-associated epitope mutations are likely to
confer escape from a CTL response [17] and to understand why
some MHC class I alleles are associated with slow rates of disease
progression [18,19].
A range of computational algorithms have been developed to
predict CTL epitopes in pathogen protein sequences. Since the
most selective requirement for a peptide to be immunogenic is the
ability of the peptide to bind to the MHC molecule, most
prediction methods focus on this stage of the pathway. As a
general rule, information gained from experimental binding assays
is used to train the algorithm until it is efficient at predicting novel
MHC–peptide complexes. The algorithms that are used vary in
complexity and accuracy. Some can be trained to recognize
peptide motifs that are required for binding to a particular MHC
molecule [20], others use a weight-matrix method to identify
amino acids that occur at a higher-than-expected frequency at
specific epitope positions [21,22,23]. However, the most accurate
methods available use logistic regression [24] and, more generally,
artificial neural networks [3].
Artificial neural networks (ANNs) take into account, in addition
to the identity of each amino acid residue, the interactions between
adjacent amino acids in a potential epitope. In summary, an ANN
for a particular MHC molecule is trained to recognize associated
inputs (a peptide sequence) and outputs (the binding affinity for
that sequence with the MHC molecule) [25]. Once an ANN is
trained for a particular molecule, it can predict the binding affinity
of novel peptide sequences.
NetCTL [3] and NetMHC [25,26,21] are two of the most
accurate prediction methods currently available [27]. NetMHC
uses ANNs for a number of alleles to predict MHC molecule-
peptide binding affinities. NetCTL, as well as using ANNs to
predict MHC – peptide binding, also utilizes information about
the proteasomal cleavage of the input peptide sequence, and its
ability to bind to TAP. NetCTL or NetMHC will predict a score
(either integrated or simply a binding affinity, respectively) for
every overlapping nonamer peptide sequence in an input sequence
to each MHC molecule for which the method has an ANN.
Henceforth, we refer to the trained prediction algorithm for each
MHC class I allele as an ‘‘allelic predictor’’.
Rescaling
In order to make the prediction values comparable between
each MHC molecule, it is recommended that the MHC-peptide
binding affinity scores are rescaled [28]; this is explicitly
implemented in NetCTL. The method of rescaling involves
obtaining the predicted binding affinities of 500,000 random
natural peptides for each MHC allelic predictor. From these
affinities, a rescale value is calculated, defined as the binding
affinity that is the threshold for the top 1% of total binding
affinities. The rescaled affinity is then defined as the predicted
affinity score divided by this rescale value [3]. Hence, from this
calculation, all alleles are predicted to bind the same number of
high-affinity peptides. One pragmatic reason for rescaling is to
correct for any discrepancies between the allelic predictors that
resulted from inconsistent training data (e.g. data that came from
different sources), by assuming that all alleles should bind the same
number of epitopes (C. Kes¸mir, pers. comm.). Additionally, there
are biological arguments for believing that different alleles should
bind similar numbers of epitopes. It has been postulated that the
opposing constraints of effective pathogen recognition but
tolerance of self would result in a very narrow range of optimal
promiscuity for viable MHC class I molecules. A narrow range of
promiscuity would also be predicted as a direct outcome of
effective tapasin-dependent peptide optimization in the endoplas-
mic reticulum [29,30,31].
However, we will present evidence in this paper that in
correcting for differences between the allelic predictors, informa-
tion is being lost that reflects true biological variation between
MHC molecules and, by extension, differences in their ability to
bind to peptide sequences. We show that, for both qualitative and
quantitative measures of binding, rescaling impairs rather than
improves allelic predictor performance. This is of importance for
vaccine design and to understand the nature of the CTL response.
In particular, crucial between-allele variations in binding affinity
and preference which may contribute to differences in the
outcome of infection are likely to be obscured by rescaling.
Methods
Prediction Method Outputs
In order to test the effect of rescaling on epitope prediction
accuracy, we used two web-based prediction methods, NetCTL
v1.2 [3] and NetMHC v3.0 [25,26,21]. NetCTL is an integrated
method that uses information pertaining to TAP and protein
cleavage in its predictions, together with MHC binding. The
output is combined by rescaling the MHC binding result and
adding this to the weighted scores for TAP and protein cleavage.
NetCTL has allelic predictors for 12 different class I alleles that are
chosen to be representative of each of 12 supertypes; hence it has
12 different rescaling factors.
NetMHC v3.0 simply predicts MHC-peptide binding, using
ANNs to predict binding affinities for 43 MHC molecules. In
order to test the effect of rescaling, it was necessary to produce
rescale values for each of the 43 allelic predictors. This was
performed as in NetCTL; 500,000 unique random nonamers were
obtained from the proteome of Mycobacterium tuberculosis, their
binding affinity was predicted and the rescale value (top percentile)
was found for each allelic predictor. We also performed this
calculation with 500,000 random natural peptides to test for the
possibility of error from bias in amino acid usage in Mycobacterium
Author Summary
The use of prediction software has become an important
tool in increasing our knowledge of infectious disease. It
allows us to predict the interaction of molecules involved
in an immune response, thereby significantly shortening
the lengthy process of experimental elucidation. A high
proportion of this software has focused on the response of
the immune system against pathogenic viruses. This
approach has produced positive results towards vaccine
design, results that would be delayed or unobtainable
using a traditional experimental approach. The current
challenge in immunological prediction software is to
predict interacting molecules to a high degree of accuracy.
To this end, we have analysed the best software currently
available at predicting the interaction between a viral
peptide and the MHC class I molecule, an interaction that
is vital in the body’s defence against viral infection. We
have improved the accuracy of this software by challeng-
ing the assumption that different MHC class I molecules
will bind to the same number of viral peptides. Our
method shows a significant improvement in correctly
predicting which viral peptides bind to MHC class I
molecules.
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tuberculosis. There was no significant difference in the rescale values
obtained using these two different sources (supplementary
material, figure S4).
In summary, we tested two sets of rescaling values: those
obtained from NetCTL v1.2 and those that we calculated using
NetMHC v3.0.
Datasets
Epitope datasets were constructed from sources detailed below.
In each case, the prediction methods were tested by their ability to
detect these epitopes amongst the full set of overlapping nonamers
derived from the proteins that contained the epitopes. The full set
of nonamers will contain a small number of known epitopes and
the remainder will be ‘non-epitopes’. Of course, this set of non-
epitopes could include epitopes that have not been experimentally
verified. However, the majority (see introduction) would be non-
binders with the corresponding MHC molecule. Added to this, the
labelling of epitopes as ‘non-epitopes’ impact on both rescaled and
non-rescaled calculations equally. Previous research has also
shown that this property of the ‘non-epitope’ set did not produce
significantly different results [24]. Each respective set of experi-
mentally defined epitopes was denoted the positive dataset and the
set of non-binding (or unknown) peptides was denoted the negative
dataset.
The SYF1 Dataset
The SYF1 dataset is a supertype dataset derived from
SYFPEITHI [20] and is identical to that used in the original
paper for NetCTL [3]. Each epitope in SYF1 was experimentally
verified to bind to one of 10 MHC class I supertypes [32]. The
resulting dataset consisted of 148 epitope-supertype pairs. The
corresponding negative dataset was obtained by concatenating the
SwissProt entry proteins from which each of the epitopes was
derived. The length of the concatenated protein sequence was
78,259 amino acids. The ROC curve (see below for explanation)
was generated using a negative set of ((78,259*10)2148) = 782,442
nonamers and a positive set of 148 nonamers. The positive set of
SYF1 is available in the supplementary material (dataset S2).
The Lanl661 Dataset
Experimentally defined epitopes in HIV-1 were extracted from
the HIV Molecular Immunology Database [33]. In total, 1,618
CTL epitopes were found that were bound by human MHC
molecules. However, this set was highly redundant; the epitope
lengths were variable and a large number of epitopes differed only
by mutations within the sequence. Also, resolution of their MHC
typing varied from 2 to 4 digits. To correct for this variability, a
number of changes were made to the MHC allele-epitope list.
Firstly, all MHC alleles were defined to two digits. Secondly,
variant epitopes binding the same allele were discarded. Finally, as
the prediction software only produced binding predictions for
nonamer epitopes, all epitopes that were not 9 amino acids long
were removed from the list.
In summary, it was possible to test 41 of the 43 allelic predictors
for MHC molecules in NetMHC v3.0. The positive set consisted
of 661 epitopes, defined in terms of start and end positions relative
to the HIV reference strain HXB2 (supplementary dataset S1) and
a matching MHC type to 2 digits. The input protein sequence to
NetMHC contained 3,000 overlapping nonamers that covered the
proteome from which the whole positive set of epitopes was
derived. The total ‘negative set’ for the ROC analysis was (3,000 *
41)2661) = 122,339 nonamers, and a positive set of 661
nonamers. The positive set of Lanl661 is available in the
supplementary material (dataset S3).
The Lanl179 Dataset
The Lanl661 dataset was modified for testing with NetCTL.
From these 661 epitopes, a total of 179 bound to the 12 alleles for
which NetCTL has allelic predictors. The input sequence to
NetCTL contained 3,000 overlapping nonamers. For this
experiment, the negative set consisted of ((3,000 * 12)2179)
35,821 nonamers, and a positive set of 179 nonamers. The positive
set of Lanl179 is available in the supplementary material (dataset
S4).
ROC Curves
ROC curves give a visual measure of the accuracy of a
prediction method. The threshold at which the prediction method
identifies a peptide as being an epitope varies along the length of
the curve. Each point on the curve gives the fraction of true
positive epitopes found as a function of the number of false positive
‘epitopes’ at that threshold. Hence, setting a strict threshold for
epitope detection will result in high specificity (correct predictions)
but low sensitivity (missing a high proportion of true binders). The
area under the ROC curve gives the AUC (Area under Curve)
measurement. In order to test for significant difference between
ROC curves, we conducted the bootstrapping analysis detailed in
[34]. Briefly, using bootstrapping with replacement, 100 replicates
were formed from each dataset and the resulting non-rescaled and
rescaled whole AUC values were compared using a paired t test.
Other Measurements of Performance
Using the 2 epitope datasets, HIV216 and SYFPEITHI863, and
the same methods from [35], we repeated 3 of the measurements
described in that paper for the rescaled and non-rescaled results of
NetCTL v1.2. For the Rank measure, we analysed the proteins
from which each epitope was derived. For each protein, we
calculated the rank of the epitope amongst all overlapping 9-mers
using rescaling and non-rescaling scoring methods for all alleles.
We then analysed these ranks to see which method ranked the
epitopes higher. For the second method, we measured the
specificity of both rescaling and non-rescaling at predefined
sensitivities. Finally, we measured the sensitivity among the top 5%
top-scoring peptides, again for the rescaled and non-rescaled
binding affinities.
Other Data Sources
The training data for NetMHC v3.0 is available at http://
mhcbindingpredictions.immuneepitope.org/. An independent set
of experimental epitope-allele binding affinities was obtained from
the Immune Epitope Database and Analysis Resource (IEDB) by
selecting all experimental data that did not originate from the
laboratories of Sette et al. or Buus et al. (the training data originated
from these two sources).
Results
The Effect of Rescaling on Qualitative Epitope Prediction
ROC curves were used to analyse the effects of rescaling on
epitope prediction. Both NetCTL v1.2 and NetMHC v3.0 were
tested and 3 datasets were used (figure 1 and table 1). In each case,
rescaling resulted in a significant loss of performance (bootstrap
test: p,0.001).
Variation in Rescale Values as a Function of Accuracy
One possible explanation for why rescaling has a detrimental
impact on prediction is that there may be a positive correlation
between rescale factor and allelic predictor accuracy. To check this
Rescaling in Epitope Prediction
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hypothesis we calculated the AUCs for each NetMHC v3.0
predictor using the Lanl661 dataset and plotted this against the
corresponding rescale factor, the results of which are shown in
figure 2. This shows no evidence of a correlation between rescaling
values and the AUC values (R2 = 0.0068, p= 0.606).
Consequently, it is unlikely that a correlation between rescale
values and AUC values explains our findings. However, certain
alleles like B0801 do have both a low rescale value and a low
AUC. To double check that these poor accuracy predictors were
not causing the inaccuracies in rescaled predictions we repeated
our ROC curve analysis for Lanl661 without the low accuracy
predictors (those with an AUC value below 0.9; namely A6801,
A6802, B3501, B0702, B0801, B0802 and B4501). In the
remaining, reduced subset of predictors there was even less
evidence for a correlation between AUC and rescale factor
(R2 = 0.0007, p = 0.887). For this subset of predictors the accuracy
was still significantly better if rescaling was not applied (figure S1;
bootstrap test: p,0.001) and comparable to the ROC curve
analysis using the full set of alleles (figure 1C).
Therefore, we believe there is no evidence to support the
hypothesis that the reason rescaling is detrimental is because there
is a correlation between rescale factors and AUC.
Figure 1. ROC curve analysis on the effects of rescaling. Each graph shows the ROC curves using different combinations of datasets and
prediction methods (see table 1). Figure 1A uses NetCTL with the SYF1 dataset, figure 1B NetMHC with the SYF1 dataset, figure 1C NetMHC with the
Lanl661 dataset and figure 1D NetCTL with the Lanl179 dataset. The x-axis has been scaled to show the region of importance (the AUC with high
specificity values). The rescaled results (red dashed line) are compared against non-rescaled (black solid line). Table 1 gives the statistics for each
graph.
doi:10.1371/journal.pcbi.1000327.g001
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Other Measurements of Performance
We used 3 other metrics [35] to compare predictive perfor-
mance with and without rescaling.
(1) The rank of known epitopes was compared with non-epitopes
from the same protein for both rescaled and non rescaled
predictions. From figure S2, it can be seen that the non-rescaled
results produced significantly more accurate results for both
epitope datasets (paired Wilcoxon ranked sum test, P,0.001).
(2) Non-rescaling predicted binding affinities produced improved
results compared to rescaling at given sensitivities using the
epitope datasets from [35] (supplementary table S1).
(3) Non-rescaling predicted binding affinities also produced
improved results comparing the total number of epitopes
among the top 5% predicted binding affinities (supplementary
table S2), again using the epitope datasets from [35].
The Effect of Rescaling on Quantitative Predictions of
Binding Affinities
Using 2 sets of experimentally-derived epitope-allele binding
affinities, we also showed that the correlation between predicted
and experimental affinities was weaker with rescaling than without
(supplementary figure S3).
Table 1. The summary statistics and details of each ROC curve from figure 1.
ROC Curve Colour Method Dataset Rescaling AUC Bootstrap P-Value
Figure 1A Black solid NetCTL v1.2 SYF1 Noa 0.949 ,0.001
Red dashed NetCTL v1.2 SYF1 Yes 0.937
Figure 1B Black solid NetMHC v3.0 SYF1 No 0.932 ,0.001
Red dashed NetMHC v3.0 SYF1 Yes 0.905
Figure 1C Black solid NetMHC v3.0 Lanl661 No 0.944 ,0.001
Red dashed NetMHC v3.0 Lanl661 Yes 0.937
Figure 1D Black solid NetCTL v1.2 Lanl179 Noa 0.933 ,0.001
Red dashed NetCTL v1.2 Lanl179 Yes 0.918
aIn NetCTL v1.2, the TAP and cleavage scores are combined with the rescaled MHC binding score to produce a combined score for each submitted nonamer. In order to
test how NetCTL performed without rescaling, it was still necessary to divide the MHC binding score by a rescaling value so the weightings of the TAP and cleavage
score were still applicable and accurate. By averaging over all rescaling values and dividing the MHC binding value by this number, rescaling differences were
‘‘averaged out’’ and it was still possible to use the extra information from the TAP and cleavage predictions.
doi:10.1371/journal.pcbi.1000327.t001
Figure 2. The relationship between AUC and rescale value. There is no evidence for a correlation of AUC and rescale value for the whole set of
allele predictors (R2 = 0.0068, p = 0.606), nor for the subset of predictors with an AUC.0.9 (R2 = 0.0007, p = 0.887). This analysis used the Lanl661
epitope dataset.
doi:10.1371/journal.pcbi.1000327.g002
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Discussion
Rescaling is, in theory, a sound approach to improving epitope
prediction and in particular comparability of predictions obtained
using different allelic predictors. However, using a number of
different measures of accuracy, in the context of two commonly
used prediction methods, we have demonstrated that rescaling
actually impairs rather than improves predictive performance and
comparability. We suggest that rescaling predicted affinities results
in a loss of information that outweighs any advantage gained in
correcting for differences in training data.
The first approach used ROC curve analysis and showed clear
differences between rescaling and non-rescaling. The ROC curve
gives a graphical representation of how well the prediction method
ranks true epitopes among a set of non-binding peptides. Or to use
an analogy, how efficient it is at finding the epitopic needle in a
haystack of random peptides. From figure 1, it is clear that
rescaling across all allelic predictors results in a performance loss in
terms of how well the method ranks its peptides by binding affinity;
that is, rescaling impairs intra-allelic comparisons. This loss could
be demonstrated using epitope data from a number of sources
(SYFPEITHI, the HIV Molecular Immunology Database) and
with two different methods of prediction (the combined approach
of NetCTL v1.2 and NetMHC v3.0). This effect of rescaling would
be detrimental to any studies screening across a number of alleles
for possible epitopes (such as [15]). The effect of this performance
difference can be gauged from figure 1 (A). In order to identify
correctly 85% of the epitopes the percentage of false positives
detected was 9% and 15%, for non-rescaled and rescaled methods
respectively. To put this result into context, the viral protein NS1
from the H5N1 strain of Avian Influenza A consists of 221
overlapping nonamers. To screen this protein for potential
epitopes, 33 epitopes would need to be experimentally checked
for each MHC molecule of interest if rescaled predictions were
used, as opposed to 20 for the non-rescaled predictions (providing
85% epitope coverage was sufficient).
Added to the significant results from the ROC curve analysis,
the supplementary analysis demonstrated the positive effect of
removing rescaling in terms of the correlation with experimental
data (supplementary figure S3) and also in terms of per-protein
and sensitivity analysis (supplementary figure S2 and tables S1 and
S2). Taken together, these results strongly demonstrate the
improvement in accuracy of removing the condition of rescaling
when comparing predictions between alleles.
There has been little research on the variation in ‘stickiness’
among MHC molecules, i.e. whether some MHC class I molecules
are capable of binding to a greater number of epitopes than others.
The binding motifs for MHC-peptide binding vary across the
range of alleles, but the assumption made for rescaling is that each
molecule would bind to the same number of peptides out of a large
random selection. Estimates based upon mass spectrometry
suggest that over 2,000 peptides are associated with HLA-A2.1
and 2B7 and it is speculated that the actual total could be over
10,000 per MHC molecule [36]. However, it is not known how
this number varies between molecules. It has been postulated that
the twin constraints of effective pathogen recognition but tolerance
of self would result in a very narrow range of promiscuity for viable
MHC class I molecules [29]. Contrary to this, recent research has
shown that this range may be wider than initially envisaged [37]
and our results suggest that there is considerable inter-allelic
variation in promiscuity.
This data may also be informative regarding optimization of
peptide cargo in the endoplasmic reticulum (ER). We would argue
that peptide optimization is the biological interpretation of
rescaling: alleles have similar numbers of epitopes because peptides
with a lower binding affinity are replaced in the ER. We know that
optimisation cannot be complete because otherwise every allele
would just present one epitope: the one with highest affinity.
However, it seems likely that there is a degree of optimization
[30,31]. The observation that rescaling gives worse predictions
may put a bound on how much optimisation is occurring. Allied to
this, it has been observed that the release of an MHC class I
molecule from the peptide-loading complex with a suboptimal peptide
takes precedence over the prolonged detention of the MHC class I
molecule in the complex until an optimal peptide comes along
[30]. Hence, peptide optimization acts to reduce inter-allelic
variation and promiscuity results from inter-allelic variation in
allele-peptide affinity. However, this peptide optimization is
limited by time and is not complete and hence, we note this
variation in promiscuity across different alleles.
In summary, we suggest that much of the observed variation
between allelic predictors reflects genuine biological information
which should not be discarded as experimental noise and that
rescaling is based on an unjustified assumption: that all alleles bind
the same number of peptides. Removing this assumption, we have
demonstrated a significantly improved predictive performance.
These conclusions are important both for studies that use
prediction methods to understand the CTL response and for T cell
epitope discovery programs where avoiding rescaling could save a
large amount of experimental effort, ultimately leading to
improved vaccine implementation.
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